Welcome to our dedicated page for Core Laboratories news (Ticker: CLB), a resource for investors and traders seeking the latest updates and insights on Core Laboratories stock.
Core Laboratories Inc. (NYSE: CLB) is an oilfield services company that focuses on reservoir description and production enhancement services and products for global oil and gas operators. The CLB news page on Stock Titan aggregates company announcements, earnings releases, and operational updates that the company issues through press releases and SEC-related disclosures.
Investors and industry followers can use this news feed to review Core Laboratories’ quarterly earnings reports, which typically include segment performance for Reservoir Description and Production Enhancement, commentary on international and offshore activity, and details on free cash flow, capital allocation, and dividends. The company’s news also covers strategic developments such as the opening of its unconventional core analysis laboratory in Dammam, Saudi Arabia, and the acquisition of Brazil-based geological services provider Solintec.
Core Laboratories’ updates frequently describe how its proprietary technologies—such as PRISM™ workflows, diagnostic tracers, and specialized energetic systems—are applied in specific client projects across regions including the Middle East, Africa, South America, the North Sea, and other key oil-producing basins. These case studies provide context on how the company’s services are used in deepwater exploration, unconventional reservoir evaluation, plug and abandonment operations, and geothermal projects.
By following CLB news, readers can monitor scheduled earnings conference calls, dividend declarations, changes to credit facilities disclosed via 8-K filings, and management’s commentary on industry conditions. Bookmark this page to access a consolidated view of Core Laboratories’ latest public communications as they are released.
Core Laboratories N.V. (CLB) reported Q4 2021 revenues of $125.1M, with an operating income of $14.2M and EPS of $0.06. The company saw a 14% year-over-year growth in international revenue. Despite challenges from COVID-19, especially in the Middle East, projects are underway, including a large reservoir evaluation. Revenue from Production Enhancement rose 15% sequentially. The Board approved a quarterly cash dividend of $0.01 per share, payable on March 7, 2022. For Q1 2022, Core expects revenue between $117M and $122M.
Core Laboratories (NYSE: CLB) will host its fourth quarter 2021 conference call on February 3, 2022, at 7:30 a.m. CST / 2:30 p.m. CET. The call features Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham discussing financial and operational results. An earnings press release will precede the call on February 2, available on the Company's website. Participants can join the live webcast or access the on-demand podcast afterward.
Core Laboratories N.V. reported Q3 2021 revenue of $118 million and operating income of $6.6 million, with EPS of $0.02. Non-GAAP operating income was $13 million, with an 11% operating margin. Revenue impacted by weather events, project delays, and supply chain issues. Reservoir Description segment revenue was $79 million, while Production Enhancement dropped 3% to $39.2 million. Free Cash Flow rose 33% to $8.8 million. A quarterly dividend of $0.01 per share was declared for Q4 2021.
Core Laboratories (CLB) will hold its third quarter 2021 conference call on October 28, 2021, at 7:30 a.m. CDT / 2:30 p.m. CEST. The earnings press release will be issued after market close on October 27. Key executives, including Larry Bruno (CEO) and Chris Hill (CFO), will discuss financial results. Interested participants can access the live webcast at www.corelab.com and a podcast will be available post-call. Core Laboratories specializes in enhancing petroleum reservoir performance.
Core Laboratories N.V. (NYSE: CLB) reported second quarter 2021 revenue of $118.7 million and an operating income of $12.8 million, resulting in a diluted EPS of $0.17. The company experienced year-over-year improvements driven by U.S. onshore activity growth and better international operations, although its Reservoir Description segment faced pandemic-related challenges. Core generated $6.6 million in free cash flow, reducing net debt by $5.8 million. The company is optimistic about future growth, projecting third quarter revenue between $122 million and $126 million.
Core Laboratories (NYSE: CLB) will host a conference call to discuss Q2 2021 results on July 29, 2021, at 7:30 a.m. CDT. The call will feature updates from key executives, including Chairman and CEO Larry Bruno and CFO Chris Hill. An earnings press release will be available after market close on July 28, 2021. Investors can access the call via a live webcast on the company's website, with a replay available for 10 days post-event. Core Laboratories, a leading provider of reservoir optimization services, operates over 70 offices in more than 50 countries.
Core Laboratories reported Q1 2021 revenue of $108.4 million, with an operating income of $11.6 million and diluted EPS of $0.18. The results were affected by a winter storm and ongoing pandemic disruptions, yet the company generated positive earnings and $5.2 million in free cash flow. The ATM program netted $59.1 million to reduce debt by 26%. Core projects a sequential revenue increase in both Reservoir Description and Production Enhancement by mid to high single digits and mid to high teens, respectively, in Q2 2021.
Core Laboratories (NYSE: CLB) will host a conference call on April 22, 2021, at 7:30 a.m. CDT to discuss its first quarter 2021 financial and operational results. The earnings press release will be released after market close on April 21, 2021. Investors can access the webcast through the company's website; recordings will be available for 10 days. CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Schreffler will present. Core Laboratories is a key provider of reservoir description and production enhancement services, operating over 70 offices globally.
Core Laboratories N.V. reported Q4 2020 revenue of $113.7 million and operating income of $23.4 million, yielding an EPS of $0.31. Adjusting for non-cash stock compensation, operating income ex-items was $13 million, with a margin of 11%. Full-year free cash flow reached $46 million, marking the 19th consecutive year of positive cash flow. The company reduced net debt by $48.7 million in 2020. Despite challenges from COVID-19, Core anticipates improved activity in the second half of 2021, particularly in international markets.
Core Laboratories N.V. (CLB) has declared a cash dividend of $0.01 per share, payable on February 16, 2021, to shareholders of record as of January 25, 2021. This first-quarter dividend marks a total potential annual payout of $0.04 per share if maintained throughout the year. The dividend is subject to a 15% Dutch withholding tax. Future dividends will depend on the company's financial performance, market conditions, and capital expenditure plans.